EAACI Congress 2024

Back
31 May - 03 June 2024 Valencia, Spain

TPS84 - Eosinophilic esophagitis

Sunday 02 Jun, 12:00 PM - 13:00 PM Valencia, Spain
Poster Zone Thematic Poster Session
Abstract Text
D3.450
Characterization of patients with Eosinophilic Esophagitis and response to first-line treatment in a Portuguese Immunoallergology Department
Abstract Text
D3.446
Clinical and atopic features of patients with primary eosinophilic colitis: an Italian multicentre study
Abstract Text
D3.448
Dupilumab improves histologic, symptomatic, and endoscopic outcomes in children with eosinophilic esophagitis in the EoE KIDS study, regardless of history of elimination diet or concomitant food allergy
Abstract Text
D3.449
Dupilumab normalized the esophageal transcriptome in children aged 1 to <12 years with eosinophilic esophagitis (EoE) in the Phase 3 EoE KIDS trial
Abstract Text
D3.457
Eosinophilic Esophagitis and Neurodevelopmental Disorders: a potential association requiring further investigations
Abstract Text
D3.456
Eosinophilic Esophagitis in Children: Challenges and Solutions in Dietary Therapy
Abstract Text
D3.452
GPR15L induces chemotaxis of GPR15+ CD4 memory T cells and may facilitate their extravasation into the esophageal mucosa in Eosinophilic Esophagitis (EoE)
Abstract Text
D3.455
Half-Dose Response To Swallowed Topıcal Cortıcosteroıds In Chıldren Wıth Eosınophılıc Esophagıtıs
Abstract Text
D3.453
IL-4 impairs the esophageal epithelial barrier function in vitro more potently than IL-13
Abstract Text
D3.454
IgE-Mediated Food Allergies in Children with Eosinophilic Esophagitis
Abstract Text
D3.451
Tissue-specific inducible expression of IL-33 elicits features of eosinophilic esophagitis

Chairs

Speakers